Trending...
- Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
- Award-Winning Heritage at South Brunswick Continues to Thrive as One of New Jersey's Premier New Home Communities
- Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
MORRISVILLE, N.C.--(BUSINESS WIRE)--Life Edit Therapeutics Inc., an ElevateBio company focused on next-generation genome editing technologies and therapeutics, today announced the appointment of Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, to its Scientific Advisory Board (SAB). Dr. Cavagnaro is an internationally recognized expert in science-based regulatory strategies and translation of research to preclinical and product development, with an emphasis on genetic medicines.
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
"We are thrilled to welcome Joy to our Scientific Advisory Board as we rapidly advance our gene editing platform to harness the vast potential of our novel nucleases and base editors as therapeutics," said Mitchell Finer, Ph.D., Chief Executive Officer, Life Edit Therapeutics and President, R&D, ElevateBio. "Joy's expertise in drug discovery and development will complement our esteemed Scientific Advisory Board slate, and collectively our advisors will continue to help Life Edit and our partners further therapeutic programs to address the tremendous unmet needs of genetically-defined diseases."
Joy A. Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS, has more than 40 years of experience in the biotechnology industry and is the President and Founder of Access BIO, where she consults globally on science-based preclinical development strategies. She served at the United States Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research (CBER) and was appointed to Senior Biomedical Research Service. Dr. Cavagnaro was also the past Chair of the Regulatory Affairs Professional Society (RAPS), President of the National Capital Area Chapter of the Society of Toxicology (SOT), and recipient of the Society's 2019 Arnold J. Lehman Award. Later this year, the American College of Toxicology is expected to recognize Dr. Cavagnaro with the Distinguished Scientist Award in Toxicology. In addition, Dr. Cavagnaro has co-authored numerous white papers, articles, and book chapters related to various aspects of preclinical safety assessment. She received her Ph.D. in Biochemistry from the University of North Carolina at Chapel Hill, followed by post-graduate work at Duke University and Boston University Medical Centers.
More on ncarol.com
- Boston Industrial Solutions Launches New Citrine® SA1-370 Silicone Glue for Permanent Adhesion
- Northeast Airlines Launches New Asset Management Group
- AI Visibility Labs LLC - Dallas Texas - July 16 2026
- NextBoat's AI-Powered Marine Marketplace Gains Momentum as Record Growth Signals an Inflection Point for Investors (N Y S E American: NXB)
- Stepping Off the Grid: Savista Retreat Announces New Experiential Packages in Jaipur for Travellers
"Life Edit holds one of the largest and most diverse arrays of novel RNA-guided nucleases and base editors that offers flexible editing and unprecedented access to the genome," said Joy Cavagnaro, Ph.D., DABT, Fellow ATS, RAC, FRAPS. "This powerful technology platform unlocks enormous potential for the development of novel therapeutics, and I look forward to working with the company as they continue to advance their gene editing platform and own internal pipeline of in vivo gene therapies for patients in need."
About Life Edit Therapeutics Inc.
Life Edit Therapeutics, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies. For more information visit lifeeditinc.com or on LinkedIn or Twitter.
More on ncarol.com
- Where Is Your Faith The Movie and Sountrack
- Bynn Intelligence Ranks #1 in NIST Child Online Safety Evaluation for Ages 13–16
- Rev-O-Box™ Launches Reversible Shipping Box That Instantly Becomes a Premium Gift Box
- Las Vegas Estate Firm Ghandi Deeter Blackham Offers Insight on Tony Hsieh's Contested $500 Million Will
- Ms. Marie's Coffee Blend Launches Local Delivery Service Beginning in Lexington, North Carolina
Contacts
Investor Contact:
Catherine Hu
chu@elevate.bio
Life Edit Media Contact:
Courtney Heath
courtney@scientpr.com
Filed Under: Business
0 Comments
Latest on ncarol.com
- New from Regal House Publishing, Call it Madness: a missing grandfather - reclaiming a ruptured life
- LawProactive Launches SB 37-Compliant Attorney Marketing Software With Exclusive City Territories Across California
- Cogs and Marvel expands EMEA leadership team for next phase of growth
- Dave Freer's "Storm-Dragon" Wins First-Ever Prometheus Special Award For Young Adult Fiction
- T. Jones Group Celebrates Two Wins and Multiple Project Nominations at the 2026 HAVAN Awards
- Studica Robotics Supports Robotics Training Camp for WorldSkills Shanghai 2026
- Lineus Medical Renews Agreement with Vizient, Delivering Enhanced Value for Vizient Members
- Qscription Technologies Appoints Radiology Industry Veteran Elliot Silverman to Advisory Board
- Search Is Broken. Curated Discovery Is the Future
- While iHeartMedia Cuts Jobs, Radio Stations Nationwide Are Hiring
- 20 Ways to Save Money Running a Van
- How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
- Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse
- Mr. Hospital Bed Helps Home Care Buyers Find the Right Hospital Bed
- The KettleBelle Achieves Explosive 400% Member Growth in Four Months, Launches 5-Day Kickstart
- Soma and Sage Bringing Functional Mobility and Nervous System Regulation to Burlington NC
- Able Rooter Expands Services to Offer Premium Water Heater Installation Across St. Louis
- Director Sean McNamara Reunites with Award-Winning Cinematographer Shawn Seifert for Upcoming Feature Home
- J. Kenton Pierce Wins Prometheus Award for Best Novel
- Class is in session: Black Beauty Block Party returns to Los Angeles for fourth annual festival